Johnson & Johnson fully endorses the goals of the Global Collaboration to Accelerate Development, Production and Equitable Access to New COVID-19 Tools.
As the largest and most comprehensive healthcare company in the world, Johnson & Johnson has been at the forefront of public health challenges, from antibiotics for TB to treatments for HIV and other infectious diseases and developing vaccines for HIV, Ebola, Zika, and much more.
We began working on a vaccine for COVID-19 the moment the sequence was announced and recently announced the selection of a lead COVID-19 vaccine candidate. We are accelerating our research & development and in parallel rapidly expanding our manufacturing capacity globally with a goal to supply more than one billion doses of a safe, effective and affordable COVID-19 vaccine on a not-for-profit basis for emergency pandemic use.
We have expedited our ongoing work to screen thousands of compounds in our libraries to identify a potential COVID-19 treatment and working on studying immunomodulators as a way to address the deadly acute respiratory distress syndrome that overcomes COVID-19 patients.
We stand ready to expand upon our multiple existing global partnerships, and participate this new collaboration to make a commitment at the upcoming 2020 global pledging event.
Johnson & Johnson is committed to leverage our breadth and global scale to put an end to this deadly pandemic.
